OpenLB
Open Library of Bioscience
Advanced Search
Journal of the European Academy of Dermatology and Venereology : JEADV
Jun, 2020;34 (6): 1263-1272.

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.

A Heratizadeh, E Haufe, D Stölzl, S Abraham, L Heinrich, A Kleinheinz, A Wollenberg, E Weisshaar, M Augustin, F Wiemers, A Zink, R von Kiedrowski, M Hilgers, M Worm, M Pawlak, M Sticherling, I Fell, C Handrick, K Schäkel, P Staubach-Renz, A Asmussen, B Schwarz, M Bell, I Effendy, T Bieber, B Homey, B Gerlach, E Tchitcherina, M Stahl, U Schwichtenberg, J Rossbacher, P Buck, M Mempel, S Beissert, T Biedermann, S Weidinger, J Schmitt, T Werfel, TREATgermany Study Group
Author Information
  1. A Heratizadeh: Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany. ORCID
  2. E Haufe: Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
  3. D Stölzl: Department of Dermatology and Allergy, Center for Inflammatory Skin Diseases, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  4. S Abraham: Department of Dermatology, University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
  5. L Heinrich: Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
  6. A Kleinheinz: Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.
  7. A Wollenberg: Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany. ORCID
  8. E Weisshaar: Occupational Dermatology, Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
  9. M Augustin: Insitute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany. ORCID
  10. F Wiemers: Practice Dr. med. Franca Wiemers, Leipzig, Germany.
  11. A Zink: Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany. ORCID
  12. R von Kiedrowski: CMSS - Company for Medical Study and Service, Selters/Westerwald, Germany.
  13. M Hilgers: Clinics for Dermatology and Allergy, University Hospital Aachen, Aachen, Germany.
  14. M Worm: Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
  15. M Pawlak: Practice Dr. med. Anika Hünermund and Mario Pawlak, Heilbad Heiligenstadt, Germany.
  16. M Sticherling: Department of Dermatology, University Hospital, Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany.
  17. I Fell: Hautmedizin Bad Soden, Bad Soden, Germany.
  18. C Handrick: Practice Dr. med. Christiane Handrick, Berlin, Germany.
  19. K Schäkel: Department of Dermatology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.
  20. P Staubach-Renz: Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany.
  21. A Asmussen: Practice Dermatologie an der Lesum, Bremen, Germany.
  22. B Schwarz: Practice Dr. med. Beate Schwarz, Langenau, Germany.
  23. M Bell: Practice Dr. Magnus Bell, Thomas Kaiser, Andernach, Germany.
  24. I Effendy: Department of Dermatology, Hospital Rosenhoehe, Bielefeld, Germany.
  25. T Bieber: Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.
  26. B Homey: Department of Dermatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany.
  27. B Gerlach: Practice Dr. med. Beatrice Gerlach, Dresden, Germany.
  28. E Tchitcherina: Practice Dr. med. Ekaterina Tchitcherina, Friedberg/Hessen, Germany.
  29. M Stahl: Practice Dr. med. Maren Stahl, Osterode, Germany.
  30. U Schwichtenberg: Hautpraxen Derma-Nord, Bremen, Germany.
  31. J Rossbacher: Hautzentrum Friedrichshain, Berlin, Germany.
  32. P Buck: Goldbek Medical, Hamburg, Germany.
  33. M Mempel: Practice Prof. Dr. med. Martin Mempel, Elmshorn, Germany.
  34. S Beissert: Department of Dermatology, University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
  35. T Biedermann: Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
  36. S Weidinger: Department of Dermatology and Allergy, Center for Inflammatory Skin Diseases, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  37. J Schmitt: Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
  38. T Werfel: Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
PMID: 31721316 DOI: 10.1111/jdv.16078

Abstract

BACKGROUND: The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate the 'real-life' situation of health care for patients with AD.
OBJECTIVES: Interim data analysis on baseline characteristics as well as current and prescribed systemic treatments of the TREATgermany registry patients.
METHODS: Patients (≥18 years) with moderate-to-severe AD [objective (o)SCORAD > 20], or with current or previous anti-inflammatory systemic treatment for AD within 24 months, were included and are followed up over at least 24 months. To assess clinical signs, the eczema area severity index (EASI, 0-72), the oSCORAD (0-83) and the Investigator Global Assessment (IGA; 6-point scale) were used. The disease severity was globally scored by the patients [Patient Global Assessment (PGA); six-step Likert scale]. Disease symptoms were assessed by the patient-oriented eczema measure (POEM, 0-28) and numeric rating scales (NRS, 0-10). Health-related quality of life was measured using the dermatological life quality index (DLQI, 0-30).
RESULTS: A total of 612 patients were recruited across 32 sites between 06/2016 and 01/2019 (mean age: 42.6 ± 14.2 years; mean oSCORAD: 40.8 ± 16.3). The mean POEM score was 16.3 ± 7.5. Pruritus was rated highest among subjective symptoms (NRS: 5.4 ± 2.7). The mean DLQI value was 11.3 ± 7.5. The frequency of arterial hypertension was lower (20.8%) compared with the general population, whilst this was higher for depression (10%). More than 60% of the patients had received systemic glucocorticosteroids, and 36.8% had received cyclosporine A prior to inclusion. Dupilumab was the leading substance documented as either 'current' (12.1%) or 'prescribed' (31.4%) at baseline.
CONCLUSIONS: These 'real-life' data clearly demonstrate the substantial disease burden. Most of TREATgermany patients were already treated with or prescribed dupilumab at baseline. Moreover, current findings indicate the urgent need for further alternative agents in order to achieve a perceptible improvement of quality of life of patients with moderate-to-severe AD.

References

Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol 2019; 123: 144-151.
Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
Schmitt J, Schmitt NM, Kirch W et al. Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch Dermatol Ges 2009; 7: 345-351.
Werfel T, Heratizadeh A, Niebuhr M et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96-103.e9.
Reekers R, Busche M, Wittmann M et al. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol 1999; 104: 466-472.
Peters EM, Michenko A, Kupfer J et al. Mental stress in atopic dermatitis-neuronal plasticity and the cholinergic system are affected in atopic dermatitis and in response to acute experimental mental stress in a randomized controlled pilot study. PLoS ONE 2014; 9: e113552.
Paternoster L, Standl M, Waage J et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet 2015; 47: 1449-1456.
Blome C, Radtke MA, Eissing L et al. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17: 163-169.
Langenbruch A, Radtke M, Franzke N et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol 2014; 28: 719-726.
Romanos M, Gerlach M, Warnke A et al. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269-273.
Ronnstad ATM, Halling-Overgaard AS, Hamann CR et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456.e30.
Haufe E, Abraham S, Heratizadeh A et al. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema: results from the German atopic eczema registry TREATgermany]. Hautarzt 2018; 69: 815-824.
Gutknecht M, Reinert R, Augustin M. Review of health economic analyses in atopic dermatitis: how diverse is the literature? Expert Rev Pharmacoecon Outcomes Res 2018; 19: 127-145.
Beikert FC, Langenbruch AK, Radtke MA et al. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res 2014; 306: 279-286.
Zuberbier T, Orlow SJ, Paller AS et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-232.
Thaci D, Simpson EL, Beck LA et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.
Beck LA, Thaci D, Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.
Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.
Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.
Schmitt J, Abraham S, Trautmann F et al. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany. J Dtsch Dermatol Ges 2017; 15: 49-59.
Williams HC, Burney PG, Strachan D et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994; 131: 397-405.
Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131: 383-396.
Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007; 157: 645-648.
Schmitt J, Spuls P, Boers M et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-1117.
Chalmers JR, Schmitt J, Apfelbacher C et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171: 1318-1325.
Schmitt J, Spuls PI, Thomas KS et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134: 800-807.
Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
Chopra R, Vakharia PP, Sacotte R et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.
Leshem YA, Hajar T, Hanifin JM et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140: 1513-1519.
Yosipovitch G, Reaney M, Mastey V et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.
Langan SM, Thomas KS, Williams HC. What is meant by a “flare” in atopic dermatitis? A systematic review and proposal. Arch Dermatol 2006; 142: 1190-1196.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Lieb W, Jacobs G, Wolf A et al. Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. J Community Genet 2019; 10: 523-530.
Charman CR, Venn AJ, Ravenscroft JC et al. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
Spuls PI, Gerbens LAA, Apfelbacher CJ et al. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across National Atopic Eczema Photo- and Systemic Therapy Registries. J Invest Dermatol 2017; 137: 2014-2016.
Ofenloch RF, Schuttelaar ML, Svensson A et al. Socioeconomic status and the prevalence of skin and atopic diseases in five European countries. Acta Derm Venereol 2019; 99: 309-314.
Taylor-Robinson DC, Williams H, Pearce A et al. Do early-life exposures explain why more advantaged children get eczema? Findings from the U.K. Millennium Cohort Study. Br J Dermatol 2016; 174: 569-578.
Augustin J, Schafer I, Augustin M et al. Analysis of patients’ willingness to be mobile, taking into account individual characteristics and two exemplary indications. J Dtsch Dermatol Ges 2017; 15: 430-438.
Young E, Stoneham MD, Petruckevitch A et al. A population study of food intolerance. Lancet 1994; 343: 1127-1130.
Heratizadeh A, Werfel T, Wollenberg A et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol 2017; 140: 845-853.e3.
Ludt S, Angelow A, Baum E et al. Hausärztliche Risikoberatung zur kardiovaskulären Prävention, S3-Leitlinie 2017, DEGAM-Leitlinie Nr. 19. In: AWMF-Register-Nr. 053-024. URL https://www.awmf.org/uploads/tx_szleitlinien/053-024l_S3_Hausaerztliche_Risikoberat_kardiovask_Praevention_2018-09.pdf (last accessed: 1 July 2019).
Busch MA, Maske UE, Ryl L et al. [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 733-739.
Thyssen JP, Hamann CR, Linneberg A et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73: 214-220.
Andersen YM, Egeberg A, Gislason GH et al. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol 2017; 76: 274-280.e1.
Hsu DY, Nardone B, West D et al. Validation of database search strategies for the epidemiological study of eczema herpeticum. Br J Dermatol 2016; 175: 220-222.
Wollenberg A. Eczema herpeticum. Chem Immunol Allergy 2012; 96: 89-95.
Traidl S, Kienlin P, Begemann G et al. Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses. J Allergy Clin Immunol 2018; 141: 1144-1147.e5.
Wollenberg A, Zoch C, Wetzel S et al. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. Br J Dermatol 2014; 170(Suppl 1): 38-43.
Eckert L, Gupta S, Gadkari A et al. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol 2019; 81: 187-195.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.
Werfel T, Heratizadeh A, Aberer W et al. S2k guideline on diagnosis and treatment of atopic dermatitis - short version. Allergo J Int 2016; 25: 82-95.

Grants

  1. /Sanofi-Aventis Deutschland GmbH

MeSH Term

Adult
Dermatitis, Atopic
Eczema
Humans
Middle Aged
Quality of Life
Registries
Severity of Illness Index
Journal Article

Word Cloud

Similar Articles

Cited By